Synthesis of a Dihydropyranonucleoside Using an Oxidative Glycosylation Reaction­ Mediated by Hypervalent Iodine

Hiroya Kan-no; Yukako Saito; Shun Omoto; Sakie Minato; Hideaki Wakamatsu; Yoshihiro Natori; Tomozumi Imamichi; Hiroki Takahata; Yuichi Yoshimura

doi:10.1055/s-0033-1340663

Synthesis, Inhaltsverzeichnis

Synthesis 2014; 46(07): 879-886
DOI: 10.1055/s-0033-1340663

paper

Synthesis of a Dihydropyranonucleoside Using an Oxidative Glycosylation Reaction Mediated by Hypervalent Iodine

Hiroya Kan-no

^aFaculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan Fax: +81(22)2752013 eMail: yoshimura@tohoku-pharm.ac.jp

,

Yukako Saito

^aFaculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan Fax: +81(22)2752013 eMail: yoshimura@tohoku-pharm.ac.jp

,

Shun Omoto

^aFaculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan Fax: +81(22)2752013 eMail: yoshimura@tohoku-pharm.ac.jp

,

Sakie Minato

^aFaculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan Fax: +81(22)2752013 eMail: yoshimura@tohoku-pharm.ac.jp

,

Hideaki Wakamatsu

^aFaculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan Fax: +81(22)2752013 eMail: yoshimura@tohoku-pharm.ac.jp

,

Yoshihiro Natori

^aFaculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan Fax: +81(22)2752013 eMail: yoshimura@tohoku-pharm.ac.jp

,

Tomozumi Imamichi

^bLeidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA

,

Hiroki Takahata*

^aFaculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan Fax: +81(22)2752013 eMail: yoshimura@tohoku-pharm.ac.jp

,

Yuichi Yoshimura*

^aFaculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan Fax: +81(22)2752013 eMail: yoshimura@tohoku-pharm.ac.jp

› Institutsangaben

Abstract

Alle Artikel dieser Rubrik

Abstract

As a part of our ongoing studies of structure–activity relationships regarding cyclohexenyl nucleosides, we were prompted to synthesize a dihydropyranonucleoside as a potential anti-HIV agent. The synthesis of a glycal moiety started from but-2-enediol, which was converted into a di-PMB derivative in several steps. The introduction of an allyl group followed by ring-closing metathesis gave a dihydropyran derivative. After isomerization of the double bond catalyzed by Wilkinson’s catalyst, the resulting glycal, 2,3-bis[(4-methoxybenzyloxy)methyl]-3,4-dihydro-2H-pyran, was subjected to an oxidative glycosylation reaction mediated by hypervalent iodine. Treatment of 2,3-bis[(4-methoxybenzyloxy)methyl]-3,4-dihydro-2H-pyran with (PhSe)₂/PhI(OAc)₂/TMSOTf (cat.) gave the desired pyranyluracils as a mixture of anomers that were converted into the final target, dihydropyranocytidine, after several manipulations and separation of the anomers.

Key words

glycosylation - nucleoside - oxidation - iodine - antiviral

Volltext

Referenzen

References
1 Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S. Proc. Natl. Acad. Sci. U.S.A. 1985; 82: 7096

2a De Clercq E. Curr. Opin. Pharmacol. 2010; 10: 507
2b Broder S. Antiviral Res. 2010; 85: 1
2c Cihlar T, Ray AS. Antiviral Res. 2010; 85: 39

3 Ichikawa E, Kato K. Curr. Med. Chem. 2001; 8: 385

4a Baba M, Pauwels R, Herdewijn P, De Clercq E, Desmyter J, Vandeputte M. Biochem. Biophys. Res. Commun. 1987; 142: 128
4b Hamamoto Y, Nakashima H, Matsui T, Matsuda A, Ueda T, Yamamoto N. Antimicrob. Agents Chemother. 1987; 31: 907

5a Gumina G, Chong Y, Choo H, Song GY, Chu CK. Curr. Top. Med. Chem. 2002; 2: 1065
5b Sabini E, Hazra S, Konrad M, Lavie A. J. Med. Chem. 2007; 50: 3004

6a Coates JA, Cammack N, Jenkinson HJ, Mutton IM, Pearson BA, Storer R, Cameron JM, Penn CR. Antimicrob. Agents Chemother. 1992; 36: 202
6b Schinazi RF, Chu CK, Peck A, McMillan A, Mathis R, Cannon D, Jeong LS, Beach JW, Choi WB, Yeola S. Antimicrob. Agents Chemother. 1992; 36: 672

7a Yoshimura Y, Asami K, Matsui H, Tanaka H, Takahata H. Org. Lett. 2006; 8: 6015
7b Yoshimura Y, Yamazaki Y, Kawahata M, Yamaguchi K, Takahata H. Tetrahedron Lett. 2007; 48: 4519
7c Yoshimura Y, Ohta M, Imahori T, Imamichi T, Takahata H. Org. Lett. 2008; 10: 3449
7d Yoshimura Y, Yamazaki Y, Saito Y, Takahata H. Tetrahedron 2009; 65: 9091
7e Yoshimura Y, Asami K, Imamichi T, Okuda T, Shiraki K, Takahata H. J. Org. Chem. 2010; 75: 4161
7f Yoshimura Y, Yamazaki Y, Saito Y, Natori Y, Imamichi T, Takahata H. Bioorg. Med. Chem. Lett. 2011; 21: 3313

8 Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, Tisdale M, Parry NR, Reardon JE, Dornsife RE, Averett DR, Krenitsky TA. Antimicrob. Agents Chemother. 1997; 41: 1082
9 Katagiri N, Shiraishi T, Sato H, Toyota A, Kaneko C, Yusa K, Oh-hara T, Tsuruno T. Biochem. Biophys. Res. Commun. 1992; 184: 154
10 Hayashi S, Norbeck DW, Rosenbrook W, Fine RL, Matsukura M, Plattner JJ, Broder S, Mitsuya H. Antimicrob. Agents Chemother. 1990; 34: 287
11 Gollner A, Altmann K.-H, Gertsch J, Mulzer J. Chem. Eur. J. 2009; 15: 5979

12a Vorbrüggen H, Krolikiewicz K, Bennua B. Chem. Ber. 1981; 114: 1234
12b Ueda T, Watanabe S.-I. Chem. Pharm. Bull. 1985; 33: 3689

13 Yoshimura Y, Kan-no H, Kiran YB, Natori Y, Saito Y, Takahata H. Synthesis 2012; 44: 1163
14 Schmidt B. J. Org. Chem. 2004; 69: 7672
15 Díaz Y, El-Laghdach A, Matheu MI, Castillón S. J. Org. Chem. 1997; 62: 1501

16a Pedersen CM, Nordstrøm LU, Bols M. J. Am. Chem. Soc. 2007; 129: 9222
16b Mydock LK, Demchenko AV. Org. Lett. 2008; 10: 2103

17 Compound 25α showed 8.8% of NOE at H6 of uracil when irradiated at H5′ and 25β revealed 6.9% of NOE at H1′ when irradiated at H5′.
18 Sekine M, Matsuzaki J, Satoh M, Hata T. J. Org. Chem. 1982; 47: 571
19 Anti-HIV-1 activities of the compounds were evaluated by suppression of HIV replication in PBMCs by p24 antigen capture assay. At any concentrations less than 100 μM, neither 6α nor 6β showed anti-HIV activity.

Zusatzmaterial

Supporting Information

Synthesis of a Dihydropyranonucleoside Using an Oxidative Glycosylation Reaction­ Mediated by Hypervalent Iodine

Synthesis of a Dihydropyranonucleoside Using an Oxidative Glycosylation Reaction Mediated by Hypervalent Iodine